CYTODEL, INC.

NEW YORK, NY · Founded 2012 · Biotech · Private

Engineered recombinant botulinum neurotoxin derivatives for targeted neuronal drug delivery

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · cytodel.com

Sector: Biotech
Headquarters: NEW YORK, NY
Founded: 2012
Latest Form D: $3.9M, Jan 2018
Total capital: $4.8M

Federal grants: $710K; 3 awards · 2022–2023; Rank in peer group#96 of 502
Private capital raised: $4.1M; 2 Form D · last Jan 2018; 105 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 3 pending

Capital timeline

Latest events

Feb 2023Federal grantHealth and Human S · Phase I · Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia$138K
Dec 2022Federal grantHealth and Human S · Phase I · Development of B8C1ad as an Orphan Drug for Iatrogenic Botulism$295K
Mar 2022Federal grantHealth and Human S · Phase I · Recombinant botulinum toxin with improved safety and effectiveness for treatment of dystonia$277K
Jan 2018Private capital raisedForm D · SEC · 2nd filing$3.9M
Apr 2017Private capital raisedForm D · SEC · 1st filing$150K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grants#96 · top 19%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Andre A. GudgerDirectorNamed in SEC Form D filings
Charles A. WeissDirectorNamed in SEC Form D filings
Margery A. FischbeinDirectorNamed in SEC Form D filings
Philip A. BandExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 3

Oct 20, 2022PendingRecombinant Botulinum Neurotoxin With Improved Safety Margin And Reduced ImmunogenicityUSPTOApplication 17765016
PendingRecombinant Botulinum Neurotoxin With Improved Safety Margin And Reduced ImmunogenicityUSPTOApplication PCTUS2020053583
PendingRecombinant Botulinum Neurotoxin With Improved Safety Margin And Reduced ImmunogenicityUSPTOApplication 62908365

LUNG THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
CLARADELE PHARMACEUTICALS, INCORPORATEDSimilar federal contract value in Biotech · null in contracts
THERMALIN DIABETES, LLCSimilar federal contract value in Biotech · null in contracts
ASYLIA THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Maia Biotechnology, Inc.Similar federal contract value in Biotech · null in contracts
Akeso Therapeutics IncSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.